Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fase I/IIa-studie av SNK01 hos deltakere med moderat Alzheimers sykdom

29. september 2026 oppdatert av: NKGen Biotech, Inc.

En fase I/IIa, studie for å evaluere sikkerheten, tolerabiliteten og den utforskende effekten av SNK01 hos deltakere med moderat Alzheimers sykdom

The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are:

  1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion
  2. Can SNK01 administration improve cognitive assessment scores and biomarkers

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

36

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Ontario
      • Ottawa, Ontario, Canada, K1Z 1G3
        • Tilbaketrukket
        • Ottawa Memory Clinic
    • California
      • Glendale, California, Forente stater, 91206
        • Rekruttering
        • Behavioral Research Specialists, LLC
        • Ta kontakt med:
      • Santa Ana, California, Forente stater, 92705
        • Rekruttering
        • Syrentis Clinical Research
        • Ta kontakt med:
      • Tarzana, California, Forente stater, 91356
        • Tilbaketrukket
        • Valiance Clinical Research
    • Florida
      • Maitland, Florida, Forente stater, 32751
        • Rekruttering
        • K2 Medical Research
        • Ta kontakt med:
      • Orlando, Florida, Forente stater, 32804
    • New Jersey
      • Newark, New Jersey, Forente stater, 07107
        • Rekruttering
        • Rutgers Health
        • Ta kontakt med:
    • New York
      • Albany, New York, Forente stater, 12208
        • Rekruttering
        • Alzheimer's Disease Research Center
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. The participant or their legally authorized representative must be willing and able to give their informed consent in writing and comply with the requirements of this study protocol. Informed consent for participants or their legally authorized representative and caregivers will be obtained before any trial-related activity. (Trial-related activities are any procedure that would not be performed during normal treatment of the participant).

  2. Participants must have a reliable study partner/caregiver (per investigator judgement for instance a family member, partner etc., guardian (must be always the same person)) who is in close contact with the patient, available on call and who is able to contribute to the assessment of the ratings of the functional endpoints at specific study visits. This person will be able to communicate in the language in which the participant is being assessed and should also serve as a backup contact for the study site. The study partner/caregiver must sign a separate informed consent form which describes their contributions during the study.

  3. Patients with diagnosis of Alzheimer's dementia according to the recommendations from the 2011 National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

  4. Age 40 to 85 years old.

  5. Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient or their legally authorized representative and documented by the study investigator.

  6. Female participants of childbearing potential must have a negative urine pregnancy test at Screening and Visit 1 before first administration of the study drug. Females of childbearing potential are defined as those who are not surgically sterile or who are not post-menopausal (i.e.: no menses for at least 1 year). Male and female participants of reproductive potential must also agree to abstinence or use acceptable form(s) of effective contraception during the study and for 30 days after the final dose of the study drug. Acceptable methods of contraception include the following:

    1. Condoms, sponges, foams, gels, diaphragms, or intrauterine device (IUD).
    2. Hormonal birth control for 30 days prior to administration of the study drug.
    3. A vasectomized sexual partner.
  7. Positive evidence for a diagnosis of AD via amyloid positron emission tomography (Amyloid PET) of the brain within the past six months.

  8. CDR-SB score of ≥ 9.5 and <16.0.

Exclusion Criteria:

  1. Substantial concomitant cerebrovascular disease defined as Fazekas Grade 3.
  2. History of a stroke/intracranial hemorrhage temporally related to the onset of worsening of cognitive impairment in the opinion of the investigator.
  3. Any substance use disorder that has not been in remission for at least 12 months
  4. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
  5. Uncontrolled cardiovascular illnesses such as chronic congestive heart failure (with or without oedema), tachycardia, arrhythmias, uncontrolled hypertension.
  6. History of cerebrovascular accident or transient ischemic attack (TIA), or unexplainable loss of consciousness within the last year.
  7. Significant pulmonary disease predisposing to hypoxia.
  8. Significant ischemic heart disease, myocardial infarction within the last two years and/or with residual angina, orthopnea, conduction defects (ECG), or any other clinically significant heart disease classified as NYHA III or IV.
  9. Significant liver disease (for example cirrhosis, active hepatitis B and C, primary or metastatic liver neoplasm).
  10. Indication of liver disease, defined by serum levels of either ALT (SGPT), AST (SGOT), or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined during screening.
  11. Significant gastrointestinal disorders (for example gastrointestinal bleeding within the last two years, malabsorption syndromes, post-gastrectomy, or active peptic ulcer disease).
  12. Immunological disorder such as per investigator judgement clinically significant allergies, Lupus erythematodes, or scleroderma.
  13. Uncontrolled/Unstable hematological disease (regardless of cause) such as refractory anemia or refractory myelosuppression.
  14. Neurological disease (such as: Lewy body dementia - primary diagnosis, Huntington's disease, Parkinson's Disease, encephalitis, epilepsy, vascular or multi-infarct dementia, stroke, congenital mental deficiency, multiple sclerosis) and psychiatric disorders (such as schizophrenia, or intellectual disability), or any other disorders impacting cognitive function.
  15. Unstable/uncontrolled major depression or anxiety within the last 12 months.
  16. History of seizures in the past three years.
  17. Uncontrolled endocrine disease such as uncontrolled diabetes mellitus or manifest hyperthyroidism, in the opinion of the investigator.
  18. Severe renal impairment defined as a GFR < 30 mL/min/1.73 m2 in the screening lab report
  19. Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or any other infection or active systemic disease.
  20. Currently being treated with anticoagulants (except aspirin at or below a prophylactic dose).
  21. Participants who are taking medications for AD, like memantine or acetylcholinesterase inhibitors (AChEI) that exceeds the normal recommended dose range or have not achieved a stable dose for the 30 days prior to enrollment.
  22. Any contraindication for performing a brain MRI and/or Amyloid PET scan.
  23. Any participant whose safety the investigator considers to be at risk from this trial's intervention.
  24. Participants with any medically unstable/uncontrolled conditions.
  25. Any suicidal behavior in the past 2 years (i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
  26. Any suicidal ideation of type 4 or 5 in the C-SSRS in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: SNK01

SNK01 will be administered as an IV infusion Q3W for up to 1 year.

SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug

Placebo komparator: Placebo

Placebo will be administered as an IV infusion Q3W for up to 1 year.

Sodium Lactate Hartmann's Solution

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of participants with dose-limiting toxicity
Tidsramme: 3 weeks

DLTs will be assessed by the review of labs, PE and AEs

3 weeks
Maximum tolerated dose determination
Tidsramme: 3 weeks

Determine the maximum tolerated dose based on the evaluation of the number of participants who experience a DLT which will then determine the RP2D.

3 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Tidsramme: 1 Year

Evaluate the safety and tolerability of SNK01 assessed by labs, PE and AEs

1 Year
Preliminary efficacy in cognitive assessment scores of CDR-SB
Tidsramme: 1 Year

Measure changes in cognitive assessment of CDR-SB from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of MMSE
Tidsramme: 1 Year

Measure changes in cognitive assessment of MMSE from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of NPI
Tidsramme: 1 Year

Measure changes in cognitive assessment of NPI from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of ADCS-ADL-Severe
Tidsramme: 1 Year

Measure changes in cognitive assessment of ADCS-ADL-Severe from baseline

1 Year
Preliminary efficacy in cognitive assessment scores of ADAS-Cog
Tidsramme: 1 Year

Measure changes in cognitive assessment of ADAS-Cog from baseline

1 Year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Changes in CSF biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
Tidsramme: 1 Year

Measure changes in CSF biomarkers as changed from baseline

1 Year
Changes in plasma biomarkers (pTau 181, Aβ42/40, GFAP, NfL)
Tidsramme: 1 Year

Measure changes in Plasma biomarkers as changed from baseline

1 Year

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

21. november 2023

Primær fullføring (Antatt)

1. mars 2028

Studiet fullført (Antatt)

1. juni 2028

Datoer for studieregistrering

Først innsendt

6. desember 2023

Først innsendt som oppfylte QC-kriteriene

2. januar 2024

Først lagt ut (Faktiske)

5. januar 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • SNK01-AD01

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere